<DOC>
	<DOCNO>NCT02255656</DOCNO>
	<brief_summary>Primary Objective : To evaluate long-term safety alemtuzumab . Secondary Objectives : To evaluate long term efficacy alemtuzumab . To evaluate safety profile patient receive Disease Modifying Treatment 's ( DMT ) follow alemtuzumab treatment . To evaluate patient-reported Quality Life ( QoL ) outcomes health resource utilization patient receive alemtuzumab . To evaluate need re-treatment alemtuzumab DMTs .</brief_summary>
	<brief_title>Phase IIIB-IV Long-Term Follow-up Study Patients Who Participated CAMMS03409</brief_title>
	<detailed_description>The total duration per patient 5.5 year . As per Study Investigator discretion , patient treat additional course alemtuzumab commercialized disease modify treatment . All patient complete CAMM03409 allow study , may include specific vulnerable population . If investigator decide treat patient course alemtuzumab , appropriate cautionary measure apply indicate approved labelling , , ex-EU country Lemtrada approve , accord investigator 's brochure .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Inclusion criterion : Patient complete least 48 month Extension Study CAMMS03409 . Signed write informed consent form . Exclusion criterion : Patient participate another investigational interventional study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>